基因导向的达塞曲匹在急性冠脉综合征后的疗效:dal-GenE研究
dal-GenE是一项双盲随机对照试验,在6147例急性冠脉综合征后1-3个月且ADCY9基因rs1967309位点为AA基因型的患者中,比较达塞曲匹600 mg每日一次与安慰剂对缺血性心血管事件的影响。中位随访39.9个月,主要终点在达塞曲匹组发生率为9.5%,安慰剂组为10.6%(HR 0.88,95%CI 0.75-1.03,P=0.12),未达统计学显著。
要点
- 在ADCY9 AA基因型ACS患者中,达塞曲匹未显著降低主要缺血性心血管事件风险。
- 心肌梗死风险在达塞曲匹组有降低趋势(HR 0.79,95%CI 0.65-0.96)。
- 预设的on-treatment敏感性分析显示主要终点事件率降低(HR 0.83,95%CI 0.70-0.98)。
核心结论
- 达塞曲匹未显著降低研究结束时主要缺血性心血管终点事件的发生风险。
- 需开展新试验验证达塞曲匹改善AA基因型患者预后的药物遗传学假说。
研究设计与样本
- dal-GenE为双盲随机对照试验,纳入急性冠脉综合征后1-3个月且ADCY9基因rs1967309位点为AA基因型的患者。
- 共6147例患者随机接受达塞曲匹600 mg每日一次或安慰剂每日一次。
- 主要终点为随机化至首次发生心血管死亡、复苏的心脏骤停、非致死性心肌梗死或非致死性卒中的时间。
主要发现
- 中位随访39.9个月,主要终点在达塞曲匹组3071例中发生292例(9.5%),安慰剂组3076例中发生327例(10.6%)(HR 0.88;95%CI 0.75-1.03;P=0.12)。
- 心肌梗死HR为0.79(95%CI 0.65-0.96),卒中HR为0.92(95%CI 0.64-1.33),心血管死亡HR为1.21(95%CI 0.91-1.60),复苏的心脏骤停HR为2.33(95%CI 0.60-9.02)。
- 预设的on-treatment敏感性分析中,主要终点事件率在达塞曲匹组为7.8%(236/3015),安慰剂组为9.3%(282/3031)(HR 0.83;95%CI 0.70-0.98)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal-GenE study was conducted to test this pharmacogenetic hypothesis. METHODS AND RESULTS: dal-GenE was a double-blind trial in patients with an acute coronary syndrome within 1-3 months and the AA genotype at variant rs1967309 in the ADCY9 gene. A total of 6147 patients were randomly assigned to receive dalcetrapib 600 mg or placebo daily. The primary endpoint was the time from randomization to first occurrence of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. After a median follow-up of 39.9 months, the primary endpoint occurred in 292 (9.5%) of 3071 patients in the dalcetrapib group and 327 (10.6%) of 3076 patients in the placebo group [hazard ratio 0.88; 95% confidence interval (CI) 0.75-1.03; P = 0.12]. The hazard ratios for the components of the primary endpoint were 0.79 (95% CI 0.65-0.96) for myocardial infarction, 0.92 (95% CI 0.64-1.33) for stroke, 1.21 (95% CI 0.91-1.60) for death from cardiovascular causes, and 2.33 (95% CI 0.60-9.02) for resuscitated cardiac arrest. In a pre-specified on-treatment sensitivity analysis, the primary endpoint event rate was 7.8% (236/3015) in the dalcetrapib group and 9.3% (282/3031) in the placebo group (hazard ratio 0.83; 95% CI 0.70-0.98). CONCLUSION: Dalcetrapib did not significantly reduce the risk of occurrence of the primary endpoint of ischaemic cardiovascular events at end of study. A new trial would be needed to test the pharmacogenetic hypothesis that dalcetrapib improves the prognosis of patients with the AA genotype. CLINICAL TRIAL REGISTRATION: Trial registration dal-GenE ClinicalTrials.gov Identifier: NCT02525939.
引用
- Tardif, Pfeffer, Kouz, et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J. 2022. PMID: 35856777. doi:10.1093/eurheartj/ehac374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。